Automated optimisation of solubility and conformational stability of antibodies and proteins.

Autor: Rosace A; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield road, CB2 1EW, Cambridge, UK.; Master in Bioinformatics for Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain.; Institute for Research in Biomedicine (IRB), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain., Bennett A; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield road, CB2 1EW, Cambridge, UK.; Department of Mammalian Expression, Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark.; BRIC, Faculty of Health and Medical Sciences, University of Copenhagen, Ole Maaløes Vej 5, 2200, Copenhagen, Denmark., Oeller M; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield road, CB2 1EW, Cambridge, UK., Mortensen MM; Department of Purification Technologies, Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark.; Faculty of Engineering and Science, Department of Biotechnology, Chemistry and Environmental Engineering, University of Aalborg, Fredrik Bajers Vej 7H, 9220, Aalborg, Denmark., Sakhnini L; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield road, CB2 1EW, Cambridge, UK.; Department of Biophysics and Injectable Formulation 2, Global Research Technologies, Novo Nordisk A/S, Måløv, 2760, Denmark., Lorenzen N; Department of Biophysics and Injectable Formulation 2, Global Research Technologies, Novo Nordisk A/S, Måløv, 2760, Denmark., Poulsen C; Department of Mammalian Expression, Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark., Sormanni P; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield road, CB2 1EW, Cambridge, UK. ps589@cam.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2023 Apr 06; Vol. 14 (1), pp. 1937. Date of Electronic Publication: 2023 Apr 06.

Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential.

Autor: Bjerre MT; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. mtbjerre@clin.au.dk (M.T.B.).; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.; Department of Urology, Aarhus University Hospital, 8200 Aarhus N, Denmark.; Department of Urology, Regional Hospital West Jutland, 7500 Holstebro, Denmark., Nørgaard M; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. mtbjerre@clin.au.dk (M.T.B.).; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark., Larsen OH; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. mtbjerre@clin.au.dk (M.T.B.).; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark., Jensen SØ; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. mtbjerre@clin.au.dk (M.T.B.).; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark., Strand SH; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. mtbjerre@clin.au.dk (M.T.B.).; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark., Østergren P; Department of Urology, Herlev andGentofte Hospital, 2730 Herlev, Denmark peter.busch.oestergren@regionh.dk (P.Ø.)., Fode M; Department of Urology, Herlev andGentofte Hospital, 2730 Herlev, Denmark peter.busch.oestergren@regionh.dk (P.Ø.)., Fredsøe J; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. mtbjerre@clin.au.dk (M.T.B.).; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark., Ulhøi BP; Department of Pathology, Aarhus University Hospital, 8200 Aarhus N, Denmark. beneulho@rm.dk., Mortensen MM; Department of Urology, Aarhus University Hospital, 8200 Aarhus N, Denmark., Jensen JB; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.; Department of Urology, Regional Hospital West Jutland, 7500 Holstebro, Denmark., Borre M; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.; Department of Urology, Aarhus University Hospital, 8200 Aarhus N, Denmark., Sørensen KD; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. mtbjerre@clin.au.dk (M.T.B.).; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.

Publikováno v: Cells [Cells] 2020 May 31; Vol. 9 (6). Date of Electronic Publication: 2020 May 31.

Whole-body MRI in assessing malignant transformation in multiple hereditary exostoses and enchondromatosis: audit results and literature review.

Autor: Jurik AG; Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Blvd 99, 8200, Aarhus N, Denmark. annejuri@rm.dk.; Department of Radiology, Aarhus University Hospital, Palle Juul-Jensens Blvd 99, 8200, Aarhus N, Denmark. annejuri@rm.dk., Jørgensen PH; Department of Orthopedic Surgery, Aarhus University Hospital, Palle Juul-Jensens Blvd 99, 8200, Aarhus N, Denmark., Mortensen MM; Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Blvd 99, 8200, Aarhus N, Denmark.

Publikováno v: Skeletal radiology [Skeletal Radiol] 2020 Jan; Vol. 49 (1), pp. 115-124. Date of Electronic Publication: 2019 Jul 05.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Autor: Ross-Adams H; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Ball S; Prostate Cancer Research Centre, University College London, London, UK., Lawrenson K; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA., Halim S; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Russell R; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Wells C; Division of Cancer Studies, King's College London, London, UK., Strand SH; Department of Molecular Medicine, Aarhus University Hospital, Denmark., Ørntoft TF; Department of Molecular Medicine, Aarhus University Hospital, Denmark., Larson M; Mayo Clinic, SW Rochester, MN, USA., Armasu S; Mayo Clinic, SW Rochester, MN, USA., Massie CE; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Asim M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Mortensen MM; Department of Urology, Aarhus University Hospital, Aarhus, Denmark., Borre M; Department of Urology, Aarhus University Hospital, Aarhus, Denmark., Woodfine K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Warren AY; Department of Pathology, Addenbrooke's Hospital, Cambridge, UK., Lamb AD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Department of Urology, Addenbrooke's Hospital, Cambridge, UK., Kay J; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Whitaker H; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Ramos-Montoya A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Murrell A; Department of Biology and Biochemistry, University of Bath, Centre for Regenerative Medicine, Claverton Down, Bath, UK., Sørensen KD; Department of Molecular Medicine, Aarhus University Hospital, Denmark., Fridley BL; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA., Goode EL; Mayo Clinic, SW Rochester, MN, USA., Gayther SA; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA., Masters J; Prostate Cancer Research Centre, University College London, London, UK., Neal DE; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Department of Urology, Addenbrooke's Hospital, Cambridge, UK., Mills IG; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.; Departments of Cancer Prevention and Urology, Institute of Cancer Research and Department of Urology, Oslo University Hospital, Oslo, Norway.; Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, UK.

Publikováno v: Oncotarget [Oncotarget] 2016 Nov 15; Vol. 7 (46), pp. 74734-74746.

High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.

Autor: Mortensen MM, Høyer S, Orntoft TF, Sørensen KD, Dyrskjøt L; Department of Molecular Medicine, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark. lars@clin.au.dk., Borre M

Publikováno v: BMC cancer [BMC Cancer] 2014 Nov 21; Vol. 14, pp. 859. Date of Electronic Publication: 2014 Nov 21.